Organocatalytic access to enantioenriched spirooxindole-based 4-methyleneazetidines by G. Rainoldi et al.
molecules
Article
Organocatalytic Access to Enantioenriched
Spirooxindole-Based 4-Methyleneazetidines
Giulia Rainoldi 1, Matteo Faltracco 2, Claudia Spatti 1, Alessandra Silvani 1,* ID
and Giordano Lesma 1
1 Department of Chemistry, University of Milan, via Golgi 19, 20133 Milan, Italy;
giulia.rainoldi@unimi.it (G.R.); claudia.spatti@studenti.unimi.it (C.S.); giordano.lesma@unimi.it (G.L.)
2 Department of Chemistry & Pharmaceutical Sciences, Amsterdam Institute of Molecules Medicines &
Systems (AIMMS), Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands;
matteofaltracco92@gmail.com
* Correspondence: alessandra.silvani@unimi.it; Tel.: +39-025-031-4080
Received: 30 October 2017; Accepted: 17 November 2017; Published: 21 November 2017
Abstract: This work describes the synthesis of enantioenriched spiro compounds, incorporating the
azetidine and the oxindole motifs. The preparation relies on a formal [2 + 2] annulation reaction of
isatin-derived N-tert-butylsulfonyl ketimines with allenoates. The asymmetric induction is secured
by an organocatalytic strategy, exploiting a bifunctional cinchona-type β-isocupridine-based catalyst.
Some post-transformation products, including unexpected spiropyrroline and 3,3-disubstituted
oxindole derivatives, are also presented.
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1. Introduction
Spirocyclic scaffolds are privileged in drug discovery, thanks to the conformational restriction
imparted by the spiro carbon, which provides an excellent strategy to improve ligand–protein binding
in many different therapeutic areas [1,2].
Among spirocycles, spirooxindoles are compounds characterized by the presence of a spiro ring
fused at the C3 position of the oxindole core. A high number of them have been reported to exert
various biological activities (i.e., antitumoral [3], anti-inflammatory [4] and antiviral [5]), quite often
associated with a relevant target-specificity. The varied bioactivities of spirooxindoles are mainly
distinguished by the kind of spiro ring fused at the C3 position, as well as by substituent moieties
both on the spiro ring and on the oxindole scaffold. These structural elements lead to the diverse but
relatively specific pharmacological profiles of this class of privileged molecules.
Owing to the therapeutic potential and, at the same time, to the synthetic challenge associated
with spirooxindoles, there is a huge interest to develop new synthetic methodologies [6], in particular
those achieving asymmetric induction by catalytic protocols [7,8].
Since the most widely exploited scaffolds so far involve the spiro junction of oxindoles with
five-membered and six-membered rings, we recently aimed to contribute to greater diversity in
this field turning our attention to four membered rings. With the notable exception of β-lactams,
four-membered rings have received limited attention from medicinal chemists until recently, with only
a few spirocyclic azetidine scaffolds proposed as new potential lead compounds [9,10].
In our ongoing work devoted to the asymmetric synthesis of spirooxindoles [11,12],
we recently reported the first highly diastereoselective entry into chiral spirooxindole-based
4-methyleneazetidines [13]. Such compounds can be considered new lead structures in drug discovery
and also versatile intermediates, thanks to the presence of the reactive carbon-carbon double bond and
of the carboxylic ester moiety (Scheme 1a).
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As a continuation of this previous achievement, we have regarded the advantages of catalytic
methods and faced the challenge of the catalytic asymmetric construction of such spirooxindole-based
azetidine ring system.
Among catalytic methods, organocatalysis has brought unprecedented progress to the
asymmetric construction of spirooxindoles [14] and 3-amino-2-oxindoles bearing tetra-substituted
stereocenters [15,16]. It is especially attractive due to the general availability and stability of
organocatalysts and mild and simple reaction conditions used.
The first asymmetric organocatalytic synthesis of 2,4-disubstituted azetidines was reported by
Zhu et al. [17] in 2011 (Scheme 1b). It relies on the formal [2 + 2] cycloaddition of N-sulfonyl-aldimines
and allenoates using a novel bifunctional quinidine derivative as catalyst. A variety of aromatic
N-sulfonyl-aldimines underwent cycloaddition with allenoates to afford R-configured azetidines in
good yields and good regio- and enantioselectivities. Two years later, Sasai et al. [18] presented the
first example of an enantioselective organocatalytic cycloaddition of allenoates involving ketimines,
and thus affording azetidines with a chiral tetrasubstituted carbon stereogenic center (Scheme 1b).
Starting from isatin-derived N-tert-butylsulfonyl ketimines, we considered their organocatalyzed,
formal [2 + 2] annulation reaction with allenoates as a high atom-economy strategy to obtain
functionalized chiral spirooxindole-based 4-methyleneazetidines. Here we demonstrate the suitability
of bifunctional cinchona alkaloids derivatives to promote such annulation, leading for the first time to
enantioenriched azetidine-based spiro compounds by means of an organocatalytic method (Scheme 1c).
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2. Results and Discussion
We started our investigation evaluating the reaction of ethyl buta-2,3-dienoate (4a) with different
N-benzylisatin-derived ketimines [19], namely N-tert-butylsulfonyl imine 1a, N-p-toluenesulfonyl
imine 2 and N-Boc imine 3 (Table 1).
All substrates 1a, 2 and 3 afforded the corresponding azetidines 6a, 7 and 8 in presence of
DABCO (entries 1–3). In the case of N-Boc ketimine 3, also the aza-Morita-Baylis-Hillman (AMBH)
product 9 was isolated in low yield. Then the same ketimines 1a, 2 and 3 have been tested in the
organocatalytic reaction, employing the quinidine-derived alkaloid β-isocupridine (β-ICD) catalyst
5a. Both N-tert-butylsulfonyl imine 1a and tosyl imine 2 afforded the expected azetidines 6a and 7 in
good yield and enantiomeric ratio (er) (entries 4 and 5), whereas in this condition the N-Boc ketimine 3
provided only the AMBH product 9 (entry 6).
Table 1. Variation of the isatin-derived ketimines. a
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N-tert-Butylsulfonyl imine 1a was selected for further optimization of the reaction conditions,
as reported in Table 2. Starting our screening testing different catalysts, we observed that typical
quinidine-derived catalysts 5b–f were unable to promote the reaction, even after prolonged reaction
times (e trie 1–5). I all cases only degradation of the starting ketimi was obs rved. Instead,
using β-isocupridine-based catalysts 5g–l, th desired azetidine 6a was obtained in all cases, with the
exception of reaction with catalyst 5h (entries 6–12).
The high conformational bias of β-ICD and its derivatives, as well as the presence of at least
a hydrogen bond donor group at the C6 position of the quinoline ring, seem to be necessary
requirements to coordinate the substrate and therefore to catalyse the reaction. Best results in terms
of both er and chemical yield have been obtained employing catalyst 5g, which was then used for
a further screening of solvents and temperature.
Performing the reaction in apolar solvents such as dichloromethane and toluene, the desired
product was observed just in very low yields (entries 13 and 14). Lowering th tem erature to 0 ◦C no
appreciable improvement of er was observed and prolonged reaction time was needed to obtain the
desired azetidine in good yield (entry 15). At −20 ◦C the reaction was completely stopped (entry 16).
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Finally, on reducing the catalyst amount (entry 17) no improved er was observed, but just extension of
the reaction time with a reduction of the chemical yield.
Table 2. Catalyst and solvent screen for the reaction of N-tert-butylsulfonyl imine 1a with ethyl
buta-2,3-dienoate (4a). a
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With the best c n itions in hand, we planned to screen N-tert-butylsulfonyl ketimines bearing
different N-substituents at the oxindole ring (1b–f, Scheme 2). Such starting compounds have been
prepared by m-chloroperbenzoic acid-mediated oxidation of the corresponding N-tert-butylsulfinyl
ketimines and immediately used without purification (see Materials and Methods for the general
synthetic procedure).
Generally, good yields and er were observed in the reaction with allenoate 4a, under the catalysis
of 5g. The presence of the bulky trityl substituent at the oxindole nitrogen led to the corresponding
spiroazetidine derivative 6c with the best yield, but with the lowest enantioselectivity. The best result
in terms of er was obtained performing the reaction with N-methyl substituted ketimine 1b, leading to
product 6b.
Depending on whether electron-withdrawing or electron-donating group was introduced at 4-, 5-
or 6-position of the benzene ring of starting ketimines (1g–j), the reactions proceeded in a different way.
Good yield and enatioselectivity were observed for the synthesis of 5-OMe substituted spiroazetidine
6g. In the presence of the electron withdrawing Cl-substituent at C5 position, a very low yield was
achieved (6h). Finally, compounds 6i and 6j were not detected in the crude, but just degradation of the
ketimine starting material was observed.
Molecules 2017, 22, 2016 5 of 13
At the end, we investigated the formal [2 + 2] annulation with a different allenoate. Considering
the possibility of a favourable pi–pi interaction with the aromatic portion of the catalyst, we selected
benzyl buta-2,3-dienoate 4b. Indeed, the corresponding azetidine 6k could be easily obtained in good
yield, even if in quite similar er.
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The absolute configuration of the major enantiomer of compound 6a was determined through
chemical correlation, exploiting a proper conversion of reference compound I [13] (Scheme 3).
More precisely, performing a selective sulfur oxidation, enantiopure compound 6a′ could be easily
obtained from compound I. Relying on comparison of both optical rotation signs and chiral HPLC
chromatograms, the (S)-configuration at the quaternary stereocenter of product 6a could be assigned
with certainty.
Molecules 2017, 22, 2016 5 of 12 
 
low yield was achieved (6h). Finally, compounds 6i and 6j were not detected in the crude, but just 
degradation of the ketimine starting material was observed. 
At the end, we investigated the formal [2 + 2] annulation with a different allenoate. Considering 
the possibility of a favourable π–π interaction with the aromatic portion of the catalyst, we selected 
benzyl buta-2,3-dienoate 4b. Indeed, the corresponding azetidine 6k could be easily obtained in 
good yield, even if in quite similar er. 
 
Scheme 2. Substrate scope for the reaction of various ketimines 1a–j with allenoates 4a,b, catalyzed 
by catalyst 5g. Reactions conditions: ketimine 1a–j (0.15 mmol), 4a,b (0.30 mmol), 5g (0.03 mmol) in 
THF (1.5 mL). Isolated yields, after purification by column chromatography on silica gel, are reported. 
Er was determined by HPLC, on a chiral stationary phase. Trt = Trityl; nd = not detected. 
  fi            
 cor elation, exploit ng a proper conversion f re e nce comp und I [13] (Scheme 3). More 
precisely, p rforming a selective sulfur oxidation, ena tiopure compound 6a′ could be  
               
  fi            
 . 
 
Scheme 3. Chemical correlation for the assignment of absolute configuration of compound 6a. For 
comparison of the chiral HPLC chromatograms of 6a and 6a′, see the Supporting Information. 
. Chemical correlation for the assignment of absolute configurati n f c mpound 6a.
F r comparison of t e chiral HPLC chromatograms of 6a and 6a’, se the Supporti g Information.
Molecules 2017, 22, 2016 6 of 13
To rationalize the stereochemical outcome, we referred to the proposed mechanism for similar
cinchona-base catalysed [2 + 2] annulation reactions [17]. Accordingly, the basic quinuclidine
moiety acts as a nucleophile activator, producing a zwitterionic allylic carbanion from the allenoate
reagent. The activated g-position of this intermediate undergoes addition to the ketimine, followed by
an intramolecular attack back from ketimine’s nitrogen, leading to the azetidine ring and catalyst’s
regeneration. From our experimental data, it results that the peculiar skeleton of β-ICD-type catalysts
(e.g., 5g), more rigid with respect to that of corresponding quinidine-catalysts (e.g., 5b), seems the only
able to bring reactants to the correct distance for a productive reaction.
Moreover, the presence of the N-Boc glycinamide unit at C6’ position in catalyst 5g ensures
a proper activation of the ketimine, through up to two hydrogen bonds. Relying on this disposition,
to minimize the steric hindrance with the catalyst’s residue, ketimine offers its Re-face to the incoming
γ-carbanion, leading to the corresponding spiroazetidine derivative in the prevailing (S)-configuration
at the C3 of the oxindole ring. On this basis, a plausible transition state for the reported reaction
is illustrated in Scheme 4, where ketimine 1b is shown coordinated to the catalyst 5g by double
H-bonding, so explaining the found superiority of the amide N-H over the O-H group in this kind
of process.
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3. Materials and Methods
3.1. General Experimental Procedures
All commercial materials (Aldrich, Fluka, St. Louis, MO, USA) were used without further
purification. All solvents were of reagent grade or HPLC grade. All reactions were carried out
under a nitrogen atmosphere unless otherwise noted. All reactions were monitored by thin layer
chromatography (TLC) on precoated silica gel 60 F254; spots were visualized with UV light or by
treatment with ninhydrin solution in ethanol. Products were purified by flash chromatography (FC)
on silica gel 60 (230–400 mesh). 1H-NMR spectra and 13C-NMR spectra were recorded on 300 and
400 MHz spectrometers (AVANCE, Bruker, Billerica, MA, USA). Chemical shifts are reported in
parts per million relative to the r sidual solvent. Multiplicities in 1 -NMR are report d s follows:
s = singlet, d = doublet, t = triplet, m = multiplet, br s = broad singlet. 13C-NMR spectra have been
recorded using the APT pulse sequence. The number of carbons reported in the 13C data are derived
from Heteronuclear Multiple Bond Correlation (HMBC) experiments. High-resolution MS spectra
were recorded with a Micromass Q-ToF micro TM mass spectrometer (W ers, Milford, MA, USA),
equipped with an ESI source. Chiral HPLC analysis was performed on a PU-2080 system (JASCO
Europe, Cremella (LC), Italy) (UV Detector and binary HPLC pump) at 254 nm. Chiralcel AD columns
were purchased from Daicel Chemical Industries® (Osaka, Japan). Optical rotator power [α]DT was
measured with a Jasco P-1030 polarimeter, equipped with a cell of 1 dm path length and 1 mL capacity.
The light used has wavelength of 589 nm (sodium D lin ).
3.1.1. General Procedure for the Synthesis of N-tert-Butylsulfonyl Ketimines 1a–j
To a solution of N-substituted isatin (1.17 mmol, 1.0 eq) in anhydrous CH2Cl2 (2.9 L, 0.4 M),
Ti(OiPr)4 (2.34 mmol, 2.0 eq) and 2-methyl-2-propanesulfinamide (1.4 mmol, 1.2 eq) were added.
The solution as refluxed until complete disappearance of the starting materials (monitored by TLC).
The reaction was quenched by adding saturated aq. NaHCO3 (15 mL) and diluted with CH2Cl2
(15 mL). The biphasic solution was filtered through a pad of Celite and the organic phase washed
with water (2 × 15 mL), dried over Na2SO4 and the solvent was evaporated under reduced pressure.
The crude was purified by flash chromatography (FC), using hexane/EtOAc/CH2Cl2 (gradient from
9:1:10 to 5/5/10) as eluent.
New compounds:
(E)-N-(1-Propyl-2-oxoindolin-3-ylidene)-2-methylpropane-2-sulfinamide. Prepared starting from N-1-propylisatin.
Orange foam, yield: 82%. 1H-NMR (300 MHz, CDCl3) δ 8.37 (m, br, 1H), 7.41 (t, J = 7.8 Hz, 1H), 7.02
(t, J = 7.8 Hz, 1H), 6.79 (d, J = 7.8 Hz, 1H), 3.66 (t, J = 7.4 Hz, 2H), 1.70 (sext, J = 7.5 Hz, 2H), 1.38
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(s, 9H), 0.96 (t, J = 7.4 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 161.0, 148.9, 144.2, 136.1, 124.9, 123.9 (2C),
109.9, 54.1, 42.5, 23.8 (3C), 21.3, 12.0; HRMS (ESI): [M + Na]+, Calcd. for C15H20N2NaO2S+ 315.1138,
found 315.1142.
(E)-N-(1-Isopropyl-2-oxoindolin-3-ylidene)-2-methylpropane-2-sulfinamide. Prepared starting from
N-isopropylisatin. Orange foam, yield: 88%. 1H-NMR (300 MHz, CDCl3) δ 8.40 (m, br, 1H), 7.41
(t, J = 7.8 Hz, 1H), 7.03 (t, J = 7.8 Hz, 1H), 6.93 (d, J = 7.7 Hz, 1H), 4.50 (hept, J = 6.8 Hz, 1H), 1.50
(d, J = 6.8 Hz, 6H), 1.39 (s, 9H); 13C-NMR (101 MHz, CDCl3) δ 162.3, 148.3, 143.9, 136.0, 123.8, 123.6 (2C),
110.9, 55.9, 45.4, 23.7 (3C), 22.8 (2C); HRMS (ESI): [M + Na]+, Calcd. for C15H20N2NaO2S+ 315.1138,
found 315.1147.
(E)-2-Methyl-N-(2-oxo-1-phenylindolin-3-ylidene)propane-2-sulfinamide. Prepared starting from
N-phenylisatin. Orange foam, yield: 76%. 1H-NMR (300 MHz, CDCl3) δ 8.46 (m, br, 1H), 7.54
(t, J = 7.6 Hz, 2H), 7.49–7.33 (m, 4H), 7.10 (t, J = 7.8 Hz, 1H), 6.80 (d, J = 7.8 Hz, 1H), 1.43 (s, 9H);
13C-NMR (101 MHz, CDCl3) δ 158.2, 152.3, 149.4, 136.1, 133.9, 130.5 (3C), 129.3 (2C), 127.0, 124.9, 124.7,
111.1, 55.9, 23.9 (3C); HRMS (ESI): [M + Na]+, Calcd. for C18H18N2NaO2S+ 349.0981, found 349.0989.
To a solution of the desired sulfinamide in CH2Cl2 (6 mL), m-CPBA (1.5 eq) was slowly added at
room temperature and the mixture was stirred until completion of the reaction (monitored by TLC).
The reaction was quenched by adding saturated aq. NaHCO3 (15 mL) and diluted with CH2Cl2 (15 mL).
The organic phase was washed with sat. NaHCO3 (2 × 40 mL), dried (Na2SO4), and concentrated.
The corresponding sulfonamide was used without further purification. New compounds:
(E)-2-Methyl-N-(2-oxo-1-tritylindolin-3-ylidene)propane-2-sulfonamide (1c). Red foamy solid, yield: 97%.
1H-NMR (300 MHz, CDCl3) δ 8.42 (d, J = 7.7 Hz, 1H), 7.49–7.37 (m, 6H), 7.37–7.19 (m, 9H), 7.11
(t, J = 7.8 Hz, 1H), 6.97 (d, J = 7.8 Hz, 1H), 6.35 (d, J = 7.8 Hz, 1H), 1.44 (s, 9H); 13C-NMR (101 MHz,
CDCl3) δ 162.1, 151.5, 144.5, 141.7 (3C), 136.9, 130.1 (6C), 128.6 (6C), 128.0 (3C), 123.9, 123.8, 117.9, 114.9,
75.9, 60.7, 24.5 (3C); HRMS (ESI): [M + Na]+, Calcd. for C31H28N2NaO3S+ 531.1716, found 531.1709.
(E)-2-Methyl-N-(2-oxo-1-propylindolin-3-ylidene)propane-2-sulfonamide (1d). Red foamy solid, yield: 95%.
1H-NMR (300 MHz, CDCl3, 7:3 mixture of two rotamers) δ 8.40 (m, br, 0.3H), 8.06 (d, J = 7.8 Hz, 0.7H),
7.50 (t, J = 7.8 Hz, 0.3H), 7.45 (t, J = 7.8 Hz, 0.7H), 7.11 (t, J = 7.8 Hz, 0.7H), 7.07 (t, J = 7.8 Hz, 0.3H),
6.93 (d, J = 7.8 Hz, 0.7H), 6.82 (t, J = 7.8 Hz, 0.3H), 3.74–3.62 (m, 2H), 1.74 (sext, br, J = 6.8 Hz, 2H),
1.62 (s, 6.3H), 1.60 (s, 2.7H), 0.99 (t, br, J = 6.8 Hz, 3H); 13C-NMR (75 MHz, CDCl3) δ 162.6, 150.4, 147.4,
139.0 and 138.5 (1C), 124.0 (2C), 116.2, 110.4 and 110.3 (1C), 60.6, 43.1 and 42.7 (1C), 24.5 (3C), 21.2 and
20.8 (1C), 12.0; HRMS (ESI): [M + Na]+, Calcd. for C15H20N2NaO3S+ 331.1087, found 331.1096.
(E)-2-(1-Isopropyl-2-oxoindolin-3-ylidene)-2-methylpropane-2-sulfonamide (1e). Red foamy solid, yield: 99%.
1H-NMR (400 MHz, CDCl3, 17:3 mixture of two rotamers) δ 8.19 (dd, J = 7.8 and 1.7 Hz, 0.15H), 8.12
(dd, J = 7.8 and 1.7 Hz, 0.85H), 7.76 (ddd, J = 8.2, 7.5 and 1.7 Hz, 0.15H), 7.73 (ddd, J = 8.2, 7.5 and
1.7 Hz, 0.85H), 7.34–7.21 (m, 2H), 4.77 (hept, J = 6.8 Hz, 1H), 1.62 (d, J = 6.9 Hz, 6H), 1.62 (s, 1.35H) 1.57
(s, 7.65H); 13C-NMR (101 MHz, CDCl3) δ 162.6, 158.0, 149.9, 138.9 and 138.5 (1C), 124.9 and 124.7 (1C),
124.0 and 123.7 (1C), 113.3, 112.0 and 111.3 (1C), 60.0, 45.7 and 45.5 (1C), 24.7 and 24.5 (3C), 19.9 (2C);
HRMS (ESI): [M + Na]+, Calcd. for C15H20N2NaO3S+ 331.1087, found 331.1081.
(E)-2-Methyl-N-(2-oxo-1-phenylindolin-3-ylidene)propane-2-sulfonamide (1f). Red foamy solid, yield: 98%.
1H-NMR (400 MHz, CDCl3, 7:3 mixture of two rotamers) δ 8.21 (dd, J = 7.9 and 1.4 Hz, 0.7H),
8.00 (d, br, J = 7.9 Hz, 0.3H), 7.69–7.53 (m, 4H), 7.44 (t, J = 7.8 Hz, 0.3H), 7.41–7.26 (m, 2.7H), 6.58
(d, J = 7.8 Hz, 1H), 1.47 (s, 9H); 13C-NMR (101 MHz, CDCl3) δ 162.2, 150.9, 143.1, 138.5 and 137.5 (1C),
133.7, 130.6 (3C), 129.6 and 129.5 (2C), 127.1, 125.0 and 124.7 (1C), 115.9, 111.4, 60.8, 24.9–24.5 (3C);
HRMS (ESI): [M + Na]+, Calcd. for C18H18N2NaO3S+ 365.0930, found 365.0939.
(E)-N-(1-Benzyl-5-methoxy-2-oxoindolin-3-ylidene)-2-methylpropane-2-sulfonamide (1g). Red foamy solid,
yield: 98%. 1H-NMR (400 MHz, CDCl3) δ 7.42–7.26 (m, 6H), 6.99 (dd, J = 8.2 and 2.6 Hz, 1H), 6.62
Molecules 2017, 22, 2016 9 of 13
(d, J = 8.3 Hz, 1H), 4.89 (s, 2H), 3.79 (s, 3H), 1.64 (s, 9H); 13C-NMR (101 MHz, CDCl3) δ 162.7, 156.7,
145.2, 144.1, 135.3, 129.7 (2C), 128.8, 128.0 (2C), 126.7, 125.6, 116.7, 111.9, 60.7, 56.7, 44.9, 24.6 (3C);
HRMS (ESI): [M + Na]+, Calcd. for C20H22N2NaO4S+ 409.1192, found 409.1186.
(E)-N-(1-Benzyl-5-chloro-2-oxoindolin-3-ylidene)-2-methylpropane-2-sulfonamide (1h). Red foamy solid,
yield: 92%. 1H-NMR (400 MHz, CDCl3, 4:1 mixture of two rotamers) δ 7.42–7.26 (m, 7H), 6.76
(d, J = 8.2 Hz, 0.2H), 6.68 (d, J = 8.2 Hz, 0.8H), 4.93 (s, 2H), 1.67 (s, 1.8H), 1.65 (s, 7.2H); 13C-NMR
(101 MHz, CDCl3) δ 161.2, 148.2, 145.6, 138.3 and 137.9 (1C), 134.7, 130.7 and 129.8 (2C), 129.9, 129.0
(2C), 128.0 (2C), 116.9, 112.2, 63.9, 45.5 and 45.0 (1C), 24.6 and 24.5 (3C); HRMS (ESI): [M + Na]+, Calcd.
for C19H19ClN2NaO3S+ 413.0697, found 413.0674.
3.1.2. General Procedure for the Synthesis of Spiroazetidines 6a–h, 6k
To a solution of the appropriate N-tert-butylsulfonyl ketimine 1a–j (0.10 mmol) and catalyst
5g (0.02 mmol) in THF (1.5 mL), allenoate 4a (or 4b, for spiroazetidine 6k) was added (0.20 mmol).
The mixture was stirred at room temperature and the conversion was monitored by TLC. The solvent
was evaporated under reduced pressure and the crude was purified by FC, using CH2Cl2/EtOAc 9/1
as eluent.
(S,E)-Ethyl-2-(1′-benzyl-1-(tert-butylsulfonyl)-2′-oxospiro[azetidine-2,3′-indolin]-4-ylidene)acetate (6a).
Pale orange foam; yield: 90%. 1H-NMR (300 MHz, CDCl3) δ 7.50 (d, br, J = 7.8 Hz, 1H), 7.19–7.38
(m, 6H), 7.08 (t, br, J = 7.7 Hz, 1H), 6.69 (d, br, J = 7.8 Hz, 1H), 5.68 (s, br, 1H), 5.04 and 4.83 (AB system,
J = 15.6 Hz, 2H), 4.16 (q, J = 7.1 Hz, 2H), 3.71 (dd, J = 15.6 and 1.9 Hz, 1H), 3.44 (dd, J = 15.6 and
1.9 Hz, 1H), 1.33 (s, 9H), 1.27 (t, J = 7.1 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 173.3, 167.3, 159.2, 143.6,
134.6, 129.0 (3C), 128.2, 127.5 (2C), 126.4, 126.2, 124.6, 113.2, 94.3, 70.6, 59.7, 58.9, 44.4, 41.8, 22.7 (3C),
14.5; [α]D25 = +12.2 (c 0.90, CHCl3); HRMS (ESI): [M + Na]
+, Calcd. for C25H28N2NaO5S+ 491.1611,
found 491.1604; enantiomeric ratio: 80:20, determined by HPLC (C-AD, Hexane/iPrOH 7:3, flow:
0.7 mL/min, λ = 254 nm): tR = 16.80 min (major) tR = 23.38 min (minor).
(S,E)-Ethyl-2-(1-(tert-butylsulfonyl)-1′-methyl-2′-oxospiro[azetidine-2,3′-indolin]-4-ylidene)acetate (6b).
Pale orange foam; yield: 91%. 1H-NMR (400 MHz, CDCl3) δ 7.50 (d, J = 7.5 Hz, 1H), 7.38 (d, J = 7.5 Hz,
1H), 7.12 (t, J = 7.5 Hz, 1H), 6.86 (d, J = 7.5 Hz, 1H), 5.66 (t, J = 1.9 Hz, 1H), 4.16 (q, J = 7.1 Hz, 2H), 3.66
(dd, J = 16.0, 1.9 Hz, 1H), 3.41 (dd, J = 16.0, 1.9 Hz, 1H), 3.24 (s, 3H), 1.32 (s, 9H), 1.23–1.30 (m, 3H);
13C-NMR (101 MHz, CDCl3) δ 173.3, 167.7, 159.4, 144.7, 131.8, 125.9, 125.0, 123.7, 109.5, 95.9, 71.7,
62.2, 60.5, 39.8, 27.3, 24.5 (3C), 15.0; [α]D25 = +19.3 (c 0.80, CHCl3); HRMS (ESI): [M + Na]
+, Calcd.
for C19H24N2NaO5S+: 415.1298, found 415.1303; enantiomeric ratio: 83:17, determined by HPLC (C-AD,
Hexane/iPrOH 7:3, flow: 0.7 mL/min, λ = 254 nm): tR = 24.96 min (major) tR = 29.58 min (minor).
(S,E)-Ethyl-2-(1-(tert-butylsulfonyl)-2′-oxo-1′-tritylspiro[azetidine-2,3′-indolin]-4-ylidene)acetate (6c).
Pale orange foam; yield: 95%. 1H-NMR (300 MHz, CDCl3) δ 7.50–7.39 (m, 7H), 7.30–7.16 (m, 9H),
7.03–6.89 (m, 2H), 6.28 (d, J = 7.4 Hz, 1H), 5.62 (t, J = 1.9 Hz, 1H), 4.19–4.05 (m, 2H), 3.58 (dd, J = 15.7,
1.9 Hz, 1H), 3.31 (dd, J = 15.7, 1.9 Hz, 1H), 1.34 (s, 9H), 1.24 (t, J = 6.8 Hz, 3H); 13C-NMR (75 MHz,
CDCl3) δ 172.9, 167.2, 9.0, 144.0, 141.7 (3C), 129.5 (7C), 127.7 (6C), 127.1 (3C), 125.6, 123.9, 122.6, 116.6,
94.9, 74.9, 71.6, 61.7, 59.8, 40.1, 24.1 (3C), 14.4; [α]D25 = −0.67 (c 1.5, CHCl3); HRMS (ESI): [M + Na]+,
Calcd. for C37H36N2NaO5S+: 643.2237, found 643.2240; enantiomeric ratio: 71:29, determined by
HPLC (C-AD, Hexane/iPrOH 7:3, flow: 0.7 mL/min, λ = 254 nm): tR = 8.00 min (major) tR = 11.84 min
(minor).
(S,E)-Ethyl-2-(1-(tert-butylsulfonyl)-2′-oxo-1′-propylspiro[azetidine-2,3′-indolin]-4-ylidene)acetate (6d).
Pale orange foam; yield: 77%. 1H-NMR (300 MHz, CDCl3) δ 7.49 (d, J = 7.4 Hz, 1H), 7.35 (td, J = 7.4 and
1.1 Hz, 1H), 7.10 (t, J = 7.4 Hz, 1H), 6.86 (d, J = 7.4 Hz, 1H), 5.65 (t, J = 1.9 Hz, 1H), 4.15 (q, J = 7.1 Hz,
2H), 3.75 (dt, J = 14.6 and 6.8 Hz, 1H), 3.63 (dd, J = 15.6 and 1.9 Hz, 1H), 3.58 (dt, J = 14.6 and 6.8 Hz,
1H), 3.39 (dd, J = 15.6 and 1.9 Hz, 1H), 1.72 (sext, J = 6.8 Hz, 2H), 1.32 (s, 9H), 1.27–1.22 (m, 3H)
0.97 (t, J = 6.8 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 173.1, 167.8, 159.6, 142.9, 131.6, 126.2, 125.1,
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123.5, 109.8, 95.7, 71.8, 60.5, 42.7, 40.0, 30.4, 24.6 (3C), 21.2, 15.1, 12.0; [α]D25 = +5.5 (c 1.02, CHCl3);
HRMS (ESI) calculated for C21H28N2NaO5S+ [M + Na]+ 443.1611, found 443.1617; enantiomeric ratio:
78:22, determined by HPLC (C-AD, Hexane/iPrOH 7:3, flow: 0.7 mL/min, λ = 254 nm): tR = 7.73 min
(major) tR = 9.85 min (minor).
(S,E)-Ethyl-2-(1-(tert-butylsulfonyl)-1′-isopropyl-2′-oxospiro[azetidine-2,3′-indolin]-4-ylidene)acetate (6e).
Pale orange foam; yield: 93%. 1H-NMR (300 MHz, CDCl3) δ 7.49 (d, J = 7.7 Hz, 1H), 7.34 (t, J = 7.7 Hz,
1H), 7.08 (t, J = 7.7 Hz, 1H), 6.99 (d, J = 7.7 Hz, 1H), 5.64 (t, J = 2.0 Hz, 1H), 4.56 (hept, J = 6.8 Hz, 1H), 4.15
(q, J = 7.6 Hz, 2H), 3.64 (dd, J = 15.9 and 2.0 Hz, 1H), 3.40 (dd, J = 15.9, 2.0 Hz, 1H), 1.50 (d, J = 6.8 Hz,
3H), 1.48 (d, J = 6.8 Hz, 3H), 1.30 (s, 9H), 1.26 (t, J = 7.6 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 172.4,
167.2, 159.1, 143.2, 130.9, 125.6, 124.8, 122.5, 110.4, 95.0, 71.1, 61.5, 59.9, 44.7, 39.1, 23.9 (3C), 19.2 (2C),
14.5; [α]D25 = +14.7 (c 0.99, CHCl3); HRMS (ESI) calculated for C21H28N2NaO5S
+ [M + Na]+ 443.1611,
found 443.1616; enantiomeric ratio 82:18, determined by HPLC (C-AD, Hexane/iPrOH 7:3, flow:
0.7 mL/min, λ = 254 nm): tR = 7.32 min (major) tR = 9.33 min (minor).
(S,E)-Ethyl-2-(1-(tert-butylsulfonyl)-2′-oxo-1′-phenylspiro[azetidine-2,3′-indolin]-4-ylidene)acetate (6f).
Pale orange foam; yield: 82%. 1H-NMR (300 MHz, CDCl3) δ 7.64–7.39 (m, 6H), 7.30 (t, J = 7.8 Hz,
1H), 7.15 (t, J = 7.8 Hz, 1H), 6.83 (d, J = 7.8 Hz, 1H), 5.68 (t, J = 2.0 Hz, 1H), 4.17 (q, J = 7.2 Hz, 2H),
3.77 (dd, J = 16.0, 2.0 Hz, 1H), 3.52 (dd, J = 16.0, 2.0 Hz, 1H), 1.33 (s, 9H), 1.27 (t, J = 7.2 Hz, 3H);
13C-NMR (101 MHz, CDCl3) δ 172.3, 167.2, 158.9, 144.6, 134.0, 131.2, 129.8 (2C), 128.5, 126.6 (2C), 125.8,
124.9, 123.5, 110.2, 95.4, 71.3, 61.6, 60.0, 39.2, 24.0 (3C), 14.5; [α]D25 = +10.3 (c 1.04, CHCl3); HRMS
(ESI) calculated for C24H26N2NaO5S+ [M + Na]+ 477.1455, found 447.1460; enantiomeric ratio: 77:23,
determined by HPLC (C-AD, Hexane/iPrOH 4:1, flow: 0.7 mL/min, λ = 254 nm): tR = 9.63 min (major)
tR = 14.79 min (minor).
(S,E)-Ethyl-2-(1′-benzyl-1-(tert-butylsulfonyl)-5′-methoxy-2′-oxospiro[azetidine-2,3′-indolin]-4-ylidene)-acetate
(6g). Pale orange foam; yield: 89%. 1H-NMR (400 MHz, CDCl3) δ 7.38–7.27 (m, 5H), 7.12 (d, J = 2.7 Hz,
1H), 6.78 (dd, J = 8.4 and 2.7 Hz, 1H), 6.60 (d, J = 8.4 Hz, 1H), 5.71 (t, J = 1.9 Hz, 1H), 5.05 and 4.81
(AB system, J = 15.8 Hz, 2H), 4.19 (q, J = 7.2 Hz, 2H), 3.78 (s, 3H), 3.75 (dd, J = 15.9 and 1.9 Hz, 1H),
3.45 (dd, J = 15.9 and 1.9 Hz, 1H), 1.38 (s, 9H), 1.30 (t, J = 7.2 Hz, 3H); 13C-NMR (101 MHz, CDCl3)
δ 172.5, 167.1, 158.8, 156.4, 136.4, 135.2, 128.8 (2C), 127.7, 127.3 (2C), 127.0, 115.4, 111.4, 110.5, 95.2,
71.5, 61.8, 59.9, 55.9, 44.3, 39.7, 24.0 (3C), 14.4; [α]D25 = +8.9 (c 0.95, CHCl3); HRMS (ESI) calculated
for C26H30N2NaO5S+ [M + Na]+ 521.1717, found 521.1720; enantiomeric ratio: 76:24, determined by
HPLC (C-AD, Hexane/iPrOH 4:1, flow: 0.7 mL/min, λ = 254 nm): tR = 15.00 min (major) tR = 20.63
min (minor).
(S,E)-Ethyl-2-(1′-benzyl-1-(tert-butylsulfonyl)-5′-chloro-2′-oxospiro[azetidine-2,3′-indolin]-4-ylidene)-acetate
(6h). Pale orange foam; yield: 26%. 1H-NMR (400 MHz, CDCl3) δ 7.52 (d, J = 2.1 Hz, 1H), 7.38–7.26
(m, 5H), 7.23 (dd, J = 8.2 and 2.1 Hz, 1H), 6.63 (d, J = 8.2 Hz, 1H), 5.71 (t, J = 2.1 Hz, 1H), 5.07 and 4.82
(AB system, J = 16.0 Hz, 2H), 4.20 (q, J = 7.1 Hz, 2H), 3.74 (dd, J = 15.9 and 2.1 Hz, 1H), 3.47 (dd, J = 15.9
and 2.1 Hz, 1H), 1.39 (s, 9H), 1.31 (t, J = 7.1 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 172.4, 166.9, 158.2,
141.6, 136.7, 134.6, 130.8, 129.0 (2C), 128.7, 127.9, 127.2 (2C), 124.7, 111.0, 95.6, 70.7, 61.8, 60.0, 44.4, 39.5,
23.9 (3C), 14.4; [α]D25 = +9.8 (c 1.05, CHCl3); HRMS (ESI) calculated for C25H27ClN2NaO5S
+ [M + Na]+
525.1221, found 525.1229; enantiomeric ratio: 72:28, determined by HPLC (C-AD, Hexane/iPrOH 4:1,
flow: 0.7 mL/min, λ = 254 nm): tR = 10.31 min (major) tR = 16.59 (minor).
(S,E)-Benzyl-2-(1′-benzyl-1-(tert-butylsulfonyl)-2′-oxospiro[azetidine-2,3′-indolin]-4-ylidene)acetate (6k).
Pale yellow foam; yield: 80%. 1H-NMR (400 MHz, CDCl3) δ 7.53 (d, br, J = 7.8 Hz, 1H), 7.44–7.23
(m, 11H), 7.11 (t, br, J = 7.7 Hz, 1H), 6.72 (d, br, J = 7.8 Hz, 1H), 5.78 (s, br, 1H), 5.19 (s, br, 2H), 5.08
and 4.84 (AB system, J = 15.8 Hz, 2H), 3.74 (d, br, J = 16.0 Hz, 1H), 3.47 (d, br, J = 16.0 Hz, 1H),
1.36 (s, 9H); 13C-NMR (101 MHz, CDCl3) δ 173.4, 167.5, 160.0, 143.9, 136.9, 135.7, 131.7, 129.5 (3C),
129.3, 129.0, 128.8, 128.4, 128.0 (3C), 126.0, 125.1, 123.8, 110.7, 95.5, 71.8, 66.6, 62.3, 44.9, 40.3, 24.6
(3C); [α]D25 = +15.0 (c 0.8, CHCl3); HRMS (ESI): [M + Na]
+, Calcd. for C30H30N2NaO5S+ 553.1768,
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found 553.1772; enantiomeric ratio: 78:22, determined by HPLC (C-AD, Hexane/iPrOH 7:3, flow:
0.7 mL/min, λ = 254 nm): tR = 16.80 min (major) tR = 23.38 min (minor).
3.1.3. Reactions of 6a
(S,E)-2-(1′-Benzyl-1-(tert-butylsulfonyl)-2′-oxospiro[azetidine-2,3′-indolin]-4-ylidene)acetic acid (7). To a solution
of 6a (0.21 mmol) in water/THF/iPrOH (1:1:1, 1.5 mL), LiOH (0.63 mmol) was added and the mixture
was stirred at room temperature. After the completion of the reaction (monitored by TLC), the reaction
mixture was quenched with a 1 M aqueous solution of HCl and extracted with CH2Cl2. The organic
layer was collected, dried over anhydrous sodium sulfate, and concentrated under reduced pressure
affording the product as a white foam (quantitative yield). 1H-NMR (400 MHz, CDCl3) δ 7.54
(d, J = 7.4 Hz, 1H), 7.41–7.23 (m, 6H), 7.12 (t, J = 7.4 Hz, 1H), 6.73 (d, J = 7.4 Hz, 1H), 5.71 (t, J = 1.9 Hz,
1H), 5.07 and 4.87 (AB system, J = 15.8 Hz, 2H), 3.76 (dd, J = 16.3 and 2.0 Hz, 1H), 3.49 (dd, J = 16.3
and 2.0 Hz, 1H), 2.05 (m, br, 1H), 1.37 (s, 9H); 13C-NMR (101 MHz, CDCl3) δ 172.6, 172.5, 161.3, 143.2,
135.0, 131.1, 128.9 (2C), 127.8, 127.3 (2C), 125.1, 124.4, 123.2, 110.1, 94.4, 71.2, 61.8, 44.3, 39.7, 23.9
(3C); [α]D25 = +5.7 (c 0.79, CHCl3); HRMS (ESI) calculated for C23H24N2NaO5S
+ [M + Na]+ 463.1298,
found 463.1289.
(S)-Ethyl-1-benzyl-1′-(tert-butylsulfonyl)-2-oxo-1′,3′-dihydrospiro[indoline-3,2′-pyrrole]-4′-carboxylate (8).
To a stirred solution of 6a (0.21 mmol) in CH2Cl2 (9 mL) at 0 ◦C, CF3SO3H (0.68 mmol) was added.
After stirring at 0 ◦C for 2 h, the mixture was neutralized with 0.1 M NaOH and extracted with
CH2Cl2 (4 × 15 mL). The combined organic phases were dried (MgSO4) and concentrated in vacuo,
affording the product as a white foam (quantitative yield). 1H-NMR (400 MHz, CDCl3) δ 7.56 (d, br,
J = 7.8 Hz, 1H), 7.40–7.25 (m, 6H), 7.05 (t, br, J = 7.7 Hz, 1H), 6.79 (d, br, J = 7.8 Hz, 1H), 6.15 (s, br,
1H), 4.97 and 4.91 (AB system, J = 15.5 Hz, 2H), 4.23 (q, J = 7.1 Hz, 2H), 3.49 (d, br, J = 16.4 Hz, 1H),
2.63 (d, br, J = 16.4 Hz, 1H), 1.46 (s, 9H), 1.38 (t, J = 7.1 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 171.1,
170.5, 169.7, 142.3, 134.7, 131.6, 129.1 (2C), 128.1, 127.3 (2C), 126.4, 125.1, 124.0, 81.2, 79.7, 66.6, 58.5, 44.2,
38.4, 24.0 (3C), 14.2; [α]D25 = +6.3 (c 0.53, CHCl3); HRMS (ESI): [M + Na]
+, Calcd. for C25H28N2NaO5S+
491.1611, found 491.1617.
(S)-Ethyl-4-(1-benzyl-3-(tert-butylsulfonamido)-2-oxoindolin-3-yl)-3-oxobutanoate (9). To a solution of 6a
(0.20 mmol) in trifluoroacetic acid (5 mL) and CH2Cl2 (2 mL), anisole (4 mmol) was added, and the
mixture was stirred for 1 h at 60 ◦C. To this saturated Na2CO3 was added and organic materials were
extracted with EtOAc. Dried and concentrated extract was subjected to FC (Hexane/EtOAc 1/1) to
give the product as a pale yellow foam (yield: 65%). 1H-NMR (400 MHz, CDCl3) δ 7.57 (d, br, J = 7.8 Hz,
1H), 7.43–7.24 (m, 5H), 7.21 (t, br, J = 7.7 Hz, 1H), 7.04 (t, J = 7.7 Hz, 1H), 6.72 (d, br, J = 7.8 Hz, 1H),
5.75 (s, br, 1H), 5.00 and 4.95 (AB system, J = 16.0 Hz, 2H), 4.15 (q, J = 7.1 Hz, 2H), 3.60 (d, J = 17.4 Hz,
1H), 3.45 and 3.40 (AB system, J = 16.0 Hz, 2H), 3.07 (d, J = 17.4 Hz, 1H), 1.34 (s, 9H), 1.22 (t, J = 7.1 Hz,
3H); 13C-NMR (101 MHz, CDCl3) δ 201.0, 174.7, 166.1, 142.4, 135.6, 129.7, 128.8 (2C), 128.7, 127.7, 127.3
(2C), 125.3, 122.9, 109.7, 61.7, 60.6, 60.3, 50.1, 49.2, 44.4, 24.1 (3C), 14.0; [α]D25 = −57.4 (c 0.50, CHCl3);
HRMS (ESI): [M + Na]+, Calcd. for C25H30N2NaO6S+ 509.1717, found 509.1711.
Supplementary Materials: The following are available online, NMR spectra of all new compounds and HPLC
chromatograms of spiroazetidines 6a–k.
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